BioXcel Therapeutics reported a quarterly loss of $0.54 per share, beating the Zacks Consensus Estimate for a loss of $0.59 by $0.05 per share. The loss also narrowed materially from $1.50 per share a year ago, indicating improved profitability trends, though the report provides no revenue or guidance details.
BioXcel Therapeutics reported a quarterly loss of $0.54 per share, beating the Zacks Consensus Estimate for a loss of $0.59 by $0.05 per share. The loss also narrowed materially from $1.50 per share a year ago, indicating improved profitability trends, though the report provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
